RTA Capital
VC Fund
San Francisco, United States
RTA Capital is a VC fund in San Francisco focused on Software and Education. RTA Capital LLC is a seed stage venture capital firm focused on information technology investments.Our exceptional international relationships assist portfolio companies in unique ways. Investment themes of particular interest to us include education, healthcare, enterprise, and consumer mobile internet.In the Vedic tradition, RTA isthe principle that guides the harmonious operation of the universe. RTA Capital seeks investments that contribute to a balanced, creative, and prosperous global society.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries RTA Capital invests in
Stages RTA Capital invests in
Countries RTA Capital invests in
Round sizes
Round size
- Seed
- $100k–$2M
- Series A
- $4.3M–$6M
- Series B
- $29M–$70M
Investment Focus
Industry
- Software 3 (23%)
- Education 3 (23%)
- Medical 2 (15%)
- E-Learning 2 (15%)
- Health Care 2 (15%)
Stage
- Seed 4 (31%)
- Series A 4 (31%)
- Series B 3 (23%)
- Convertible Note 2 (15%)
Country
- United States 8 (62%)
- China 1 (8%)
- Italy 1 (8%)
- Turkey 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Genz Biotech
|
Genz is a biotech research & development company, developing novel diagnostic solutions for complex diseases, like cancer, coronavirus pandemic. Genz provides solutions for medical centers and/or end-users in cooperation with genetic disease and diagnostic centers. To date, Genz received 4 R&D grants and approval by Turkish Ministryof Health for 3 genetic tests. | $100K / Seed / Jul 08, 2020 | |
Arcus Biosciences
|
Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant(AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio.Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen. | $70M / Series B / Sep 01, 2016 | |
Liulishuo
|
Liulishuo is a leading artificial intelligence-driven educational technology company founded in September 2012 by Dr. Wang Wei and Dr. Hu Zhe and Dr. Lin Hui. Liulishuo offers a personalized and adaptive language learning experience to 50 million learners in 379 cities in China and over 175 countries around the world. Its self-developed artificialintelligence English teacher, based on deep learning technology, can provide personalized and adaptive learning courses for each user. | $28.9M / Series B / Jul 15, 2015 | |
Omlet
|
Omlet is a company that offers beautifully designed pet houses. | Convertible Note / Jul 05, 2015 | |
NoRedInk
|
NoRedInk helps millions of students in grades 4-12 become better writers. Our writing platform allows learners to improve through engaging, adaptive exercises and a proven process for self-review and peer-review — and then delivers actionable performance data to teachers and administrators. Used in more than 50% of school districts in the US,we're on a mission to unlock every writer's potential. | $6M / Series A / Feb 18, 2015 | |
Payactiv
|
As a Public Benefit Corporation and Certified B Corp, we believe that people and economies flourish when everyone is able to fully participate.We liberate earned wages from pay-cycle lag time, by providing timely access to money, revolutionizing how people earn, access, and use wages.Thriving comes after surviving. Financial wellness beginsafter all livelihood needs are met - our livelihood app does just that for the modern workforce. | $4.3M / Series A / Jun 20, 2014 | |
Brilliant.org
|
Brilliant delivers digital interactive STEM learning experiences to students, professionals, and lifelong learners around the world. | Series B / May 19, 2014 | |
|
Liulishuo
|
Liulishuo is a leading artificial intelligence-driven educational technology company founded in September 2012 by Dr. Wang Wei and Dr. Hu Zhe and Dr. Lin Hui. Liulishuo offers a personalized and adaptive language learning experience to 50 million learners in 379 cities in China and over 175 countries around the world. Its self-developed artificialintelligence English teacher, based on deep learning technology, can provide personalized and adaptive learning courses for each user. | Series A / Apr 14, 2014 | |
SoundFocus
|
SoundFocus was founded with the goal of building revolutionary audio processing technologies to empower millions of people to hear better in their everyday lives.SoundFocus lets you hear music in full fidelity when listening to your iPhone or iPod Touch by tuning the audio to your hearing pattern and compensating for the sound frequencies youdo not hear well. | $1.7M / Seed / Feb 20, 2014 | |
Heap
|
Heap automates away the annoying parts of analytics so that companies can focus on making smarter business decisions. The company's mission is to power business decisions with truth. It encourages companies to focus on discovering insights and taking action. With Heap, organizations can remove technical jams and obtain a single comprehensiveview of the customers. The software automatically gathers, organizes, analyzes, and connects customer data, so businesses can create more valuable products and experiences. Heap serves over 6,000 companies in ecommerce, SaaS, fintech, retail, media, and beyond including Twilio, LendingClub, App Annie, Optimizely, Morningstar, Monotype, and Casper. Heap was founded on 2013 and is headquartered in San Francisco, California. | $2M / Seed / Aug 27, 2013 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does RTA Capital invest in?
RTA Capital invests primarily in Software, Education and Medical startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is RTA Capital's check size?
RTA Capital typically joins rounds of $100k–$2M at Seed, $4.3M–$6M at Series A and $29M–$70M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds RTA Capital participates in.
When did RTA Capital last invest?
The most recent investment recorded for RTA Capital closed in Jul 2020. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
